

Antonio Di Biagio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7868556/antonio-di-biagio-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

336
papers

5,164
citations

30
h-index

59
g-index

373
ext. papers

6,802
ext. citations

5
avg, IF

5.1
L-index

#	Paper	IF	Citations
336	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children.. <i>BMC Infectious Diseases</i> , 2022 , 22, 55	4	
335	Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C". <i>Journal of Medical Virology</i> , 2022 , 94, 436-438	19.7	
334	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment.. <i>Frontiers in Immunology</i> , 2022 , 13, 847816	8.4	
333	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022 , 14, 1028	6.2	1
332	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2021 , 141, 147	6.3	3
331	Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 338-345	1.7	3
330	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. <i>BMC Infectious Diseases</i> , 2021 , 21, 1038	4	1
329	Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021 , 591, 92-98	50.4	451
328	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1038.e1-1038.e6	9.5	
327	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. <i>EBioMedicine</i> , 2021 , 65, 103246	8.8	25
326	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. <i>ELife</i> , 2021 , 10,	8.9	51
325	The impact of DAA-mediated HCV eradication on CD4 and CD8 T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 779-786	3.4	2
324	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab217	1	16
323	Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. <i>BMC Infectious Diseases</i> , 2021 , 21, 353	4	8
322	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609	3.3	
321	Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. <i>Future Microbiology</i> , 2021 , 16, 399-407	2.9	
320	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021 , 17, e1009448	7.6	18

319	Characterization of T lymphocytes in severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2021 , 93, 5608-5613	19.7	10
318	Evaluating fostemsavir as a therapeutic option for patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1539-1545	4	0
317	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 768-776	8	1
316	General Practitioners as partners for a shared management of chronic HIV infection: An insight into the perspectives of Italian People Living with HIV. <i>PLoS ONE</i> , 2021 , 16, e0254404	3.7	0
315	The role of hepatitis B vaccine challenge dose in patients with underlying health conditions. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 575-579	4.4	1
314	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. <i>Journal of Nephrology</i> , 2021 , 34, 173-183	4.8	26
313	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 443-456	5.5	0
312	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 1664-1665	4.4	1
311	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021 , 22, 283-293	2.7	2
310	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. <i>Tuberculosis</i> , 2021 , 126, 102041	2.6	0
309	Buruli ulcer in a traveller returning from Madagascar: the first report of Mycobacterium ulcerans infection from the region. <i>Journal of Travel Medicine</i> , 2021 , 28,	12.9	1
308	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 86, 119-127	3.1	2
307	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	4
306	Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. <i>European Journal of Human Genetics</i> , 2021 , 29, 745-759	5.3	20
305	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 387-398	6.2	9
304	Injectable Antiretroviral Drugs: Back to the Future. <i>Viruses</i> , 2021 , 13,	6.2	3
303	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. <i>Liver International</i> , 2021 , 41, 1802-1814	7.9	8
302	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	28

301	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. <i>Frontiers in Pediatrics</i> , 2021 , 9, 665764	3.4	3
300	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021 , 35, 342-353	5.8	4
299	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 88, 132-137	3.1	4
298	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.. <i>Genes and Immunity</i> , 2021 ,	4.4	4
297	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13319	4.6	118
296	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. <i>Microorganisms</i> , 2020 , 8,	4.9	3
295	Clofazimine: an old drug for never-ending diseases. <i>Future Microbiology</i> , 2020 , 15, 557-566	2.9	9
294	Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2570-2584	15.1	14
293	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV Infection (INACTIION) cohort. <i>HIV Medicine</i> , 2020 , 21, 523-535	2.7	2
292	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa195	1	22
291	The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. <i>Aids</i> , 2020 , 34, 877-881	3.5	29
290	Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2100-2100	5.1	3
289	Reuse of Clinical COVID-19 Patient Data: Pre-Processing for Future Classification. <i>Studies in Health Technology and Informatics</i> , 2020 , 275, 117-121	0.5	
288	The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. <i>Journal of Preventive Medicine and Hygiene</i> , 2020 , 61, E451-E463	1.4	
287	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (INACTIION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020 , 5, 8-33	4.9	5
286	The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5515-5520	4.4	8
285	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015-2017. <i>BMC Public Health</i> , 2020 , 20, 738	4.1	0
284	HIV and tuberculosis: The paradox of dual illnesses and the challenges of their fighting in the history. <i>Tuberculosis</i> , 2020 , 122, 101921	2.6	9

283	How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. <i>Journal of Clinical Virology</i> , 2020 , 123, 104255	14.5	8
282	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 681-689	5.1	2
281	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. <i>Aids</i> , 2020 , 34, 53-61	3.5	7
280	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa456	1	5
279	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020 , 15, e0240550	3.7	1
278	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020 , 34, 1983-1985	3.5	16
277	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 496-503	3.1	2
276	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤ 50 copies/mL: does estimated glomerular filtration rate matter?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106154	14.3	1
275	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2905-2916 ³	11.6	16
274	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020 , 130, 104534	14.5	3
273	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. <i>European Journal of Human Genetics</i> , 2020 , 28, 1602-1614	5.3	132
272	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 172, 297-305	8	4
271	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13358	4.6	2
270	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020 , 12,	6.2	5
269	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1537-1544	9.5	50
268	Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19". <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa321	1	4
267	Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients?. <i>Aids</i> , 2020 , 34, 1865-1867	3.5	2
266	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020 , 15, e0237831	3.7	62

265	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020 , 8,	4.9	3
264	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 19-26	1.6	4
263	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 48-57	1.6	5
262	Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. <i>Journal of Travel Medicine</i> , 2020 , 27,	12.9	9
261	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 2020 , 15, e0237831		
260	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia 2020 , 15, e0237831		
259	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019 , 19, 1291	4.1	3
258	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019 , 16, 21	3	3
257	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3295-3304	5.1	12
256	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4. <i>PLoS ONE</i> , 2019 , 14, e0222650	3.7	6
255	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227	5.4	24
254	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1363-1367	5.1	17
253	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1857-1865	5.3	2
252	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2019 , 19, 555	4	12
251	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts $\geq 5 \log_{10}$ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2732-2741	5.1	5
250	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. <i>AIDS Research and Therapy</i> , 2019 , 16, 11	3	9
249	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019 , 116, 23-28	14.5	3
248	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. <i>Infectious Diseases</i> , 2019 , 51, 452-455	3.1	2

247	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019 , 393, 2428-2438	4.0	363
246	Missed opportunities to prevent mother-to-child transmission of HIV in Italy. <i>HIV Medicine</i> , 2019 , 20, 330-336	2.7	6
245	Bloodstream infections in patients living with HIV in the modern cART era. <i>Scientific Reports</i> , 2019 , 9, 5418	4.9	3
244	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 1443-1446	9.5	6
243	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. <i>PLoS ONE</i> , 2019 , 14, e0223181	3.7	13
242	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019 , 18, 2325958218821657	1.7	3
241	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. <i>Journal of Virus Eradication</i> , 2019 , 5, 47-49	2.8	
240	Response to letter to the editor: switch to dolutegravir and unboosted atazanavir. <i>Aids</i> , 2019 , 33, 2263-2264		
239	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, e17-e21	3.1	2
238	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019 , 393, 143-155	4.0	175
237	Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort. <i>HIV Medicine</i> , 2019 , 20, 137-146	2.7	9
236	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Name for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019 , 20, 99-109	2.7	11
235	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019 , 37, 255-266	4.4	8
234	HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 189-193	2.2	2
233	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. <i>Journal of Women and Aging</i> , 2019 , 31, 176-188	1.4	
232	The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons. <i>Journal of Frailty & Aging, the</i> , 2019 , 8, 10-16	2.6	7
231	The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research. <i>Studies in Health Technology and Informatics</i> , 2019 , 264, 1666-1667	0.5	
230	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. <i>AIDS Reviews</i> , 2018 , 20, 75-82	1.5	2

229	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. <i>Epidemiology and Infection</i> , 2018 , 146, 606-611	4.3	5
228	From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved DoctorsNWork and PatientsNCare. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 239-240	1.6	14
227	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 740-746	2.9	27
226	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. <i>ERJ Open Research</i> , 2018 , 4,	3.5	2
225	Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAT substudy. <i>Antiviral Therapy</i> , 2018 , 23, 633-637	1.6	2
224	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018 , 76, 44-54	18.9	7
223	CD8CD28CD127CD39 regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 141, 2220-2233.e4	11.5	14
222	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
221	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). <i>Journal of Clinical Virology</i> , 2018 , 105, 112-117	14.5	9
220	Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. <i>HIV Medicine</i> , 2018 , 19, 619-628	2.7	21
219	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018 , 16, 79	11.4	16
218	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018 , 18, 357	4	21
217	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018 , 18, 870	4.1	13
216	Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 922-928	1.6	8
215	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. <i>Multidisciplinary Respiratory Medicine</i> , 2018 , 13, 33	3	7
214	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. <i>Infection and Drug Resistance</i> , 2018 , 11, 615-623	4.2	11
213	Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters. <i>Immunology Letters</i> , 2018 , 203, 112-115	4.1	
212	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30

211	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113	1	34
210	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0190302	3.7	4
209	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir + ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0192627	3.7	5
208	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018 , 13, 190-197	1.6	1
207	Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. <i>Clinical Nephrology Case Studies</i> , 2018 , 6, 31-35	1.3	1
206	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 177-182	5.1	18
205	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 168-170	1.6	
204	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. <i>Frontiers in Immunology</i> , 2018 , 9, 2447	8.4	0
203	Treatment of hepatitis C virus genotype 4 in the DAA era. <i>Virology Journal</i> , 2018 , 15, 180	6.1	12
202	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018 , 19, 158-162		2
201	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018 , 13, 3-11	1.6	14
200	Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. <i>BMC Infectious Diseases</i> , 2018 , 18, 690	4	12
199	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. <i>BMC Health Services Research</i> , 2018 , 18, 691	2.9	6
198	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3460-3470	5.1	7
197	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. <i>Current Hypertension Reviews</i> , 2018 , 14, 48-55	2.3	1
196	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475	2.7	10
195	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
194	Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment. <i>Aids</i> , 2018 , 32, 1202-1203	3.5	

193	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1955-1964	5.1	20
192	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2018 , 41, 247-255	1.1	9
191	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
190	Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 19-20	1.6	
189	Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017 , 29, 1373-1377	2.2	5
188	Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. <i>International Journal of STD and AIDS</i> , 2017 , 28, 1067-1073	1.4	1
187	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^5$ cp/mL. <i>Infection</i> , 2017 , 45, 521-528	5.8	9
186	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, e76-e79	2.4	5
185	Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study. <i>Epidemiology and Infection</i> , 2017 , 145, 1658-1669	4.3	5
184	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 267.e1-267.e4	9.5	7
183	Control of the HIV-1 DNA Reservoir Is Associated and with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. <i>Journal of Virology</i> , 2017 , 91,	6.6	25
182	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017 , 12, e0177352	3.7	11
181	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , 2017 , 12, e0179254	3.7	15
180	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017 , 12, e0181433	3.7	5
179	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. <i>PLoS ONE</i> , 2017 , 12, e0189425	3.7	3
178	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx2391		55
177	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017 , 17, 551	4	71
176	Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 281-293	1.7	1

175	Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. <i>Infection</i> , 2017 , 45, 849-856	5.8	28
174	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
173	Xpert HIV-1 Viral Load Assay and VERSANT HIV-1 RNA 1.5 Assay: A Performance Comparison. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 74, e86-e88	3.1	9
172	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ After Reaching (or Starting From) Values Higher than 350 Cells/ μ in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 417-422	3.1	1
171	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017 , 31, 487-494	5.8	4
170	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 465-471	3.1	3
169	Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?. <i>BMC Infectious Diseases</i> , 2017 , 17, 127	4	3
168	Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study. <i>Virulence</i> , 2017 , 8, 101-108	4.7	4
167	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. <i>Aids</i> , 2017 , 31, 375-384	3.5	1
166	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005237	4.8	15
165	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017 , 12, e0187393	3.7	9
164	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017 , 19,	1.5	3
163	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1163-1171	5.1	56
162	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2017 , 64, 680-683	11.6	7
161	Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. <i>New Microbiologica</i> , 2017 , 40, 139-142	1.1	4
160	A Web Based Tool to Enhance Monitoring and Retention in Care for Tuberculosis Affected Patients. <i>Studies in Health Technology and Informatics</i> , 2017 , 237, 204-208	0.5	2
159	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. <i>New Microbiologica</i> , 2017 , 40, 86-98	1.1	18
158	Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents. <i>New Microbiologica</i> , 2017 , 40, 227-233	1.1	3

157	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 551-554	14.3	7
156	Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. <i>Journal of Hepatology</i> , 2016 , 64, S763	13.4	3
155	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. <i>Vaccine</i> , 2016 , 34, 5587-5594	4.1	1
154	Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw192	1	
153	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2663-9	5.1	9
152	Effectiveness of first-generation HCV protease inhibitors: does HIV coinfection still play a role?. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 37-41	2.2	2
151	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 739-50	5.1	12
150	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1637-42	5.1	5
149	Bloodstream infections in HIV-infected patients. <i>Virulence</i> , 2016 , 7, 320-8	4.7	25
148	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 288.e1-8	9.5	27
147	Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. <i>ClinicoEconomics and Outcomes Research</i> , 2016 , 8, 15-21	1.7	7
146	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016 , 11, e0160761	3.7	4
145	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016 , 11, e0156360	3.7	
144	Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. <i>PLoS ONE</i> , 2016 , 11, e0164753	3.7	35
143	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. <i>PLoS ONE</i> , 2016 , 11, e0146097	3.7	16
142	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 263-71	3.1	33
141	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw009	1	16
140	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1323	11.6	2

139	Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. <i>Journal of Chemotherapy</i> , 2016 , 28, 337-40	2.3	2
138	Onychomadesis in a male patient with secondary syphilis. <i>International Journal of STD and AIDS</i> , 2016 , 27, 704-5	1.4	1
137	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , 2015 , 12, e1001809	11.6	107
136	Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts. <i>Journal of Infection</i> , 2015 , 70, 690-4	18.9	5
135	Role of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and treatment of sarcoidosis in an HIV-2-infected patient. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 868-9	1.6	
134	Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database. <i>Infection</i> , 2015 , 43, 339-43	5.8	9
133	Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. <i>International Journal of STD and AIDS</i> , 2015 , 26, 831-4	1.4	3
132	Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, 705-10	2.4	2
131	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 289-94	14.3	23
130	Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 263-9	4.4	10
129	Behind the screens: Clinical decision support methodologies – A review. <i>Health Policy and Technology</i> , 2015 , 4, 29-38	4.8	19
128	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
127	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80	3.4	6
126	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. <i>HIV Medicine</i> , 2015 , 16, 412-20	2.7	2
125	Emergency exit of bone-marrow-resident CD34(+)DNAM-1(bright)CXCR4(+)-committed lymphoid precursors during chronic infection and inflammation. <i>Nature Communications</i> , 2015 , 6, 8109	17.4	16
124	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. <i>Aids</i> , 2015 , 29, 2061-2	3.5	2
123	Major differences in organization and availability of health care and medicines for HIV/TB coinfecting patients across Europe. <i>HIV Medicine</i> , 2015 , 16, 544-52	2.7	15
122	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015 , 10, e0124252	3.7	5

121	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015 , 10, e0140877	3.7	7
120	Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. <i>Patient Preference and Adherence</i> , 2015 , 9, 1213-8	2.4	6
119	Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. <i>European Journal of Pediatrics</i> , 2015 , 174, 843-6	4.1	1
118	Disseminated histoplasmosis with mucocutaneous immune reconstitution inflammatory syndrome in an HIV-infected patient. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 274-5	1.6	3
117	Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience. <i>Journal of the Association of Nurses in AIDS Care</i> , 2015 , 26, 652-9	1.6	13
116	Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. <i>HIV Clinical Trials</i> , 2015 , 16, 190-6		7
115	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 233-6	7.5	7
114	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. <i>Digestive and Liver Disease</i> , 2015 , 47, 157-63	3.3	5
113	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015 , 2, e98-106	7.8	172
112	IANUA: a regional project for the determination of costs in HIV-infected patients. <i>Studies in Health Technology and Informatics</i> , 2015 , 210, 241-5	0.5	3
111	State of the Art of Dual Therapy in 2015. <i>AIDS Reviews</i> , 2015 , 17, 127-34	1.5	6
110	Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection. <i>In Vivo</i> , 2015 , 29, 771-5	2.3	2
109	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014 , 42, 61-71	5.8	7
108	Gender differences in HIV infection: is there a problem? Analysis from the SCOLTA cohorts. <i>Biomedicine and Pharmacotherapy</i> , 2014 , 68, 385-90	7.5	9
107	Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. <i>HIV Clinical Trials</i> , 2014 , 15, 140-50		7
106	Pegylated interferon β plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014 , 46, 826-32	3.3	11
105	Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort. <i>HIV Clinical Trials</i> , 2014 , 15, 151-60		9
104	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 735-41	5.1	15

103	The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection. <i>BMC Infectious Diseases</i> , 2014 , 14, 277	4	14
102	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 189-94	14.3	11
101	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19825	5.4	5
100	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19718	5.4	1
99	Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2014 , 9, 41-51	1.6	1
98	The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. <i>HIV Clinical Trials</i> , 2014 , 15, 87-91		9
97	Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy. <i>HIV Clinical Trials</i> , 2014 , 15, 45-50		7
96	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. <i>Aids</i> , 2014 , 28, 609-12	3.5	6
95	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. <i>Journal of Medical Virology</i> , 2014 , 86, 1648-55	19.7	15
94	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3085-94	5.1	6
93	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. <i>Aids</i> , 2014 , 28, 1071-4	3.5	5
92	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , 2014 , 28, 2269-79	3.5	19
91	Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. <i>American Journal of Hypertension</i> , 2014 , 27, 222-8	2.3	53
90	Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7620-1	5.9	3
89	Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV. <i>Indian Journal of Pediatrics</i> , 2014 , 81, 856-60	3	1
88	Darunavir-based dual therapy in HIV experienced patients. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19782	5.4	
87	Novel antiretroviral drugs and renal function monitoring of HIV patients. <i>AIDS Reviews</i> , 2014 , 16, 144-51	1.5	29
86	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. <i>New Microbiologica</i> , 2014 , 37, 439-48	1.1	2

85	Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. <i>Immunology Letters</i> , 2013 , 152, 16-24	4.1	26
84	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). <i>Biomedicine and Pharmacotherapy</i> , 2013 , 67, 293-8	7.5	14
83	Inflammation Markers Correlate With Common Carotid Intima-Media Thickness in Patients Perinatally Infected With Human Immunodeficiency Virus 1. <i>Journal of Ultrasound in Medicine</i> , 2013 , 32, 763-768	2.9	2
82	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 200-5	5.1	14
81	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , 2013 , 2013, 373601	3	7
80	Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. <i>Journal of Chemotherapy</i> , 2013 , 25, 181-3	2.3	11
79	Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA). <i>Clinical Microbiology and Infection</i> , 2013 , 19, E443-6	9.5	1
78	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. <i>Clinical Microbiology and Infection</i> , 2013 , 19, 936-42	9.5	9
77	Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 11970-5	11.5	59
76	Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. <i>PLoS ONE</i> , 2013 , 8, e80157	3.7	31
75	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. <i>Journal of Preventive Medicine and Hygiene</i> , 2013 , 54, 83-6	1.4	7
74	The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. <i>Current HIV Research</i> , 2013 , 11, 179-86	1.3	6
73	The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. <i>Medicine 2 0</i> , 2013 , 2, e5		16
72	Inflammation markers correlate with common carotid intima-media thickness in patients perinatally infected with human immunodeficiency virus 1. <i>Journal of Ultrasound in Medicine</i> , 2013 , 32, 763-8	2.9	10
71	Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. <i>Journal of Infection and Chemotherapy</i> , 2012 , 18, 587-90	2.2	3
70	Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012 , 24, 54-8	2.2	12
69	96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. <i>PLoS ONE</i> , 2012 , 7, e39222	3.7	12
68	Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012 , 84, 1340-3	19.7	6

67	HIV and accelerated atheroprogession: role of antiretroviral therapy. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 88-96	2.6	8
66	Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. <i>Aids</i> , 2012 , 26, 2412-5	3.5	25
65	Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection. <i>Journal of Chemotherapy</i> , 2012 , 24, 56-8	2.3	1
64	Renal complications in HIV disease: between present and future. <i>AIDS Reviews</i> , 2012 , 14, 37-53	1.5	24
63	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012 , 35, 17-25	1.1	19
62	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. <i>ClinicoEconomics and Outcomes Research</i> , 2011 , 3, 197-205	1.7	19
61	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 1352-5	9.5	6
60	Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. <i>Journal of Bone and Mineral Metabolism</i> , 2011 , 29, 383-8	2.9	17
59	A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen. <i>BMC Medical Informatics and Decision Making</i> , 2011 , 11, 40	3.6	6
58	Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. <i>Journal of Medical Virology</i> , 2011 , 83, 1905-8	19.7	3
57	Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults. <i>Current Drug Safety</i> , 2011 , 6, 138-44	1.4	1
56	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1886-96	5.1	39
55	Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. <i>Clinical Nephrology</i> , 2011 , 75, 518-23	2.1	12
54	Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. <i>Aids</i> , 2010 , 24, 1013-8	3.5	27
53	Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally. <i>Journal of Medical Virology</i> , 2010 , 82, 1110-4	19.7	5
52	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). <i>HIV Medicine</i> , 2010 , 11, 530-4	2.7	6
51	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206	1.1	35
50	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9

49	Evaluation of insulin resistance in a cohort of HIV-infected youth. <i>Current Diabetes Reports</i> , 2009 , 9, 260-3.6	1
48	Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. <i>Clinical and Experimental Immunology</i> , 2009 , 158, 55-63	6.2 1
47	Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. <i>Journal of Medical Case Reports</i> , 2009 , 3, 8136	1.2 9
46	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. <i>Aids</i> , 2009 , 23, 534-8	3.5 28
45	Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. <i>European Journal of Medical Research</i> , 2009 , 14, 136-8	4.8 1
44	Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. <i>AIDS Patient Care and STDs</i> , 2008 , 22, 355-7	5.8 9
43	Different evidence of key amprenavir resistance mutations on the efficacy of darunavir. <i>Aids</i> , 2008 , 22, 437-8	3.5 2
42	Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. <i>Pediatric Infectious Disease Journal</i> , 2008 , 27, 17-21	3.4 21
41	Therapeutical aspects and outcome of HIV/HCV coinfecting patients treated with pegylated interferon plus ribavirin in an Italian cohort. <i>Infection</i> , 2008 , 36, 358-61	5.8 11
40	Infectious complications of cancer chemotherapy in HIV patients. <i>Current Infectious Disease Reports</i> , 2008 , 10, 149-56	3.9 3
39	Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 228-30	14.3 1
38	Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. <i>Infection</i> , 2007 , 35, 451-6	5.8 3
37	Persistence of <i>Candida albicans</i> candidemia in non-neutropenic surgical patients: management of a representative patient in the absence of second-line treatment guidelines. <i>Journal of Chemotherapy</i> , 2007 , 19, 335-8	2.3 1
36	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 433-5	5.1 39
35	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 39-47	3.1 31
34	Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1168-71	5.1 24
33	Penetration of didanosine in semen of HIV-1-infected men. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1244-7	5.1 9
32	Benign lymphoepithelial parotid lesions in vertically HIV-infected patients. <i>AIDS Patient Care and STDs</i> , 2006 , 20, 536-41	5.8 4

31	Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 132-8	1.6	13
30	Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2006 , 4, 875-85	5.5	17
29	Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 582-5	14.3	2
28	Clinically stable treatment-experienced adults receiving tenofovir and didanosine. <i>HIV Clinical Trials</i> , 2006 , 7, 10-5		2
27	Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. <i>International Journal of Antimicrobial Agents</i> , 2005 , 26, 88-91	14.3	26
26	Consecutive blood lactate assessment in HIV-infected children: correlation with therapy and clinical characteristics. <i>International Journal of Infectious Diseases</i> , 2005 , 9, 173-5	10.5	0
25	Role of linezolid in the treatment of orthopedic infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005 , 3, 343-52	5.5	10
24	Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 1003-7	5.1	3
23	Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 927-32	1.6	29
22	Linezolid in the treatment of Gram-positive prosthetic joint infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 387-90	5.1	88
21	Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 575-7	5.1	22
20	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (. <i>HIV Medicine</i> , 2004 , 5, 1-10	2.7	13
19	Tenofovir use in a patient with a severe renal impairment. <i>HIV Medicine</i> , 2004 , 5, 450-1	2.7	1
18	Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 83-4	14.3	21
17	New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci. <i>Reviews in Medical Microbiology</i> , 2004 , 15, 109-117	1.1	4
16	. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-670	3.4	2
15	Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-670	3.4	19
14	Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 668-70	3.4	4

13	Gram-positive bacterial resistance. A challenge for the next millennium. <i>Panminerva Medica</i> , 2002 , 44, 179-84	2	10
12	Linezolid treatment of prosthetic hip Infections due to methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <i>Journal of Infection</i> , 2001 , 43, 148-9	18.9	46
11	The effect of formulary restriction in the use of antibiotics in an Italian hospital. <i>European Journal of Clinical Pharmacology</i> , 2001 , 57, 529-34	2.8	34
10	The organization of infection control in Italy. <i>Journal of Hospital Infection</i> , 2001 , 48, 83-5	6.9	5
9	Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. <i>International Journal of Antimicrobial Agents</i> , 2000 , 16, 295-9	14.3	26
8	Use of antibiotics in an Italian children's hospital, 1993-1995; clinical and economic considerations. <i>International Journal of Antimicrobial Agents</i> , 2000 , 14, 33-7	14.3	3
7	<i>Streptococcus pyogenes</i> erythromycin resistance in Italy. <i>Emerging Infectious Diseases</i> , 1999 , 5, 302-3	10.2	14
6	Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 704-11	3.8	9
5	Fluoroquinolones in the Treatment of Atypical Mycobacterial Infections in AIDS. <i>Drugs</i> , 1999 , 58, 402-403	2.1	
4	The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. <i>Aids</i> , 1999 , 13, 2083-9	3.5	137
3	Influence of indinavir and ritonavir on warfarin anticoagulant activity. <i>Aids</i> , 1998 , 12, 825-6	3.5	15
2	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia		8
1	The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient: a case study		8